Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: A UK health economics analysis

International Journal of Clinical Practice

Volumn 61, Issue 10, 2007, Pages 1626-1633

  Palmer, A J ^a   Valentine, W J ^a   Ray, J A ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN;

ARTICLE; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE COURSE; DRUG COST; HEALTH ECONOMICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFE EXPECTANCY; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY SAMPLE; SURVIVAL TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; COHORT STUDIES; COMPUTER SIMULATION; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GREAT BRITAIN; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548618324     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01343.x     Document Type: Article

References (31)

1. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabet Med 2002 19 (Suppl. 4 1 5.
2. Stengel B, Billon S, van Dijk PC et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003 18 : 1824 33.
3. Lamping DL, Constantinovici N, Roderick P et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000 356 : 1543 50.
4. NICE. Management of Type 2 Diabetes - Renal Disease, Prevention and Early Management. London: NICE, 2002.
5. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 345 : 910 2.
6. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 345 : 851 60.
7. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 345 : 861 9.
8. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004 27 : 1897 903.
9. UK Renal Registry Report 2002. Bristol : UK Renal Registry, 2002.
10. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 63 : 225 32.
11. NHS UK Transplant Statistics. 2002. http://www.uktransplant.org.uk (accessed February 2002).
12. Clarke P, Gray A, Legood R et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003 20 : 442 50.
13. MacLeod A, Grant A, Donaldson C et al. Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. Health Technology Assessment 1998 2 : 1 184.
14. Mowatt G, Vale L, Perez J et al. Systematic review of the effectiveness and cost-effectiveness and economic evaluation of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technology Assessment 2003 17 : 1 182.
15. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisals. London: NICE, 2004.
16. Lacourciere Y, Nadeau A, Poirier L, Tancrede G. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993 21 (6 Pt 1 786 94.
17. Lebovitz HE, Wiegmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994 45 : S150 5.
18. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995 8 : 876 83.
19. Agardh CD, Garcia-Puig J, Charbonnel B et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996 10 : 185 92.
20. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998 21 : 597 603.
21. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999 353 : 617 22.
22. Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensin- converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000 57 : 590 600.
23. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000 23 (Suppl. 2 B54 64.
24. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996 19 : 1051 61.
25. Schadlich PK, Brecht JG, Brunetti M et al. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 2001 19 (5 Pt 1 497 512.
26. Ruggenenti P, Pagano E, Tammuzzo L et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001 59 : 286 94.
27. Hendry BM, Viberti GC, Hummel S et al. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM 1997 90 : 277 82.
28. Clark WF, Churchill DN, Forwell L et al. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000 162 : 195 8.
29. Le Pen C, Petitjean P, Levy P, Hannedouche T. Economic evaluation of the contribution of captopril in the treatment of diabetic nephropathy: a cost-benefit approach. Nephrologie 1996 17 : 321 6.
30. Rodby RA, Chiou CF, Borenstein J et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003 25 : 2103 19.
31. Palmer AJ, Annemans L, Roze S et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004 18 : 733 8.